IMDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Insight Molecular Diagnostics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$2.89−0.12 (-3.99%)
Close on Oct 19, 2026
- Market cap
- $106.21M
- P/E (TTM)
- –
- Dividend yield
- –
Insight Molecular Diagnostics Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Laboratory Services [Member] | $218.00K | $32.00K | $1.14M | $260.00K | $494.00K | $2.14M | $1.49M | $115.00K | $104.00K | – | – | 91.2% | -55.9% |
| Kitted Products [Member] | $21.00K | $0 | $0 | $0 | $24.00K | $0 | $0 | $0 | $0 | – | – | 8.8% | -12.5% |
| Laboratory Developed Test Services [Member] | – | – | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $22.00K | – | – | – |
| Pharma Services [Member] | – | – | – | – | – | $2.14M | – | – | – | $154.00K | – | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $218.00K | $32.00K | $1.14M | $260.00K | $494.00K | $2.14M | $1.47M | $115.00K | $67.00K | $22.00K | – | 91.2% | -55.9% |
| Europe [Member] | $15.00K | – | $0 | $0 | $24.00K | – | $18.00K | $0 | $0 | – | – | 6.3% | -37.5% |
| Asia Pacific [Member] | $6.00K | – | $0 | $0 | $0 | $0 | – | $0 | $37.00K | $109.00K | – | 2.5% | – |
| United Kingdom | – | – | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $45.00K | – | – | – |
From the segment and revenue-disaggregation notes of Insight Molecular Diagnostics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.